The Effects of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT-2-i) on Fatty Liver, Steato-Hepatitis, Liver Fibrosis, and Hepatocellular Carcinoma-A Review

The drug category of Sodium-Glucose co-transporters 2 inhibitors (SGLT 2 inhibitors) is a newer class of pharmaceutical agents for the management of type-2 diabetes mellitus, with a proved promising cardio-protective effects. In addition to above beneficial effects, Sodium-Glucose co-transporters 2 inhibitors showed their effectiveness to reduce abdominal fat content, amount of fat in liver tissues and progression of inflammation and fibrosis in...